Published in Gut on August 19, 2013
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis (2014) 1.22
Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 1.06
Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05
EpCAM and the biology of hepatic stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol (2014) 0.99
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
Common histological patterns in glomerular epithelial cells in secondary focal segmental glomerulosclerosis. Kidney Int (2015) 0.94
Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells. J Cell Mol Med (2016) 0.93
Illuminating breast cancer invasion: diverse roles for cell-cell interactions. Curr Opin Cell Biol (2014) 0.91
CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection. PLoS One (2016) 0.84
Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis. Oncotarget (2015) 0.84
Time-dependent effect of hypoxia on tumor progression and liver progenitor cell markers in primary liver tumors. PLoS One (2015) 0.84
SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis. J Pathol Transl Med (2015) 0.82
Lineage factors and differentiation states in lung cancer progression. Oncogene (2015) 0.81
Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology (2016) 0.80
Stem/Progenitor Cell Niches Involved in Hepatic and Biliary Regeneration. Stem Cells Int (2016) 0.79
Cancer stem cells in primary liver cancers: pathological concepts and imaging findings. Korean J Radiol (2015) 0.79
The rs3957357C>T SNP in GSTA1 Is Associated with a Higher Risk of Occurrence of Hepatocellular Carcinoma in European Individuals. PLoS One (2016) 0.78
Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma. J Pathol Transl Med (2015) 0.78
Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep (2015) 0.78
A role for CD81 and hepatitis C virus in hepatoma mobility. Viruses (2014) 0.78
Association Between Expression of Cancer Stem Cell Markers and Poor Differentiation of Hepatocellular Carcinoma: A Meta-Analysis (PRISMA). Medicine (Baltimore) (2015) 0.78
PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer. Gene Expr (2015) 0.78
DJ-1 deficiency attenuates expansion of liver progenitor cells through modulating the inflammatory and fibrogenic niches. Cell Death Dis (2016) 0.77
Invasive leader cells: metastatic oncotarget. Oncotarget (2014) 0.77
Advances in hepatic stem/progenitor cell biology. EXCLI J (2015) 0.77
Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience (2015) 0.77
Phosphorylation and Reorganization of Keratin Networks: Implications for Carcinogenesis and Epithelial Mesenchymal Transition. Biomol Ther (Seoul) (2015) 0.76
Identification of critical genes and gene interaction networks that mediate osteosarcoma metastasis to the lungs. Exp Ther Med (2015) 0.76
Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. Oncotarget (2016) 0.75
Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol (2017) 0.75
A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis. Oncotarget (2017) 0.75
KRT19 directly interacts with β-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties. Oncogene (2016) 0.75
Keratin 19 as a key molecule in progression of human hepatocellular carcinomas through invasion and angiogenesis. BMC Cancer (2016) 0.75
Premalignant alteration assessment in liver-like tissue derived from embryonic stem cells by aristolochic acid I exposure. Oncotarget (2016) 0.75
The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma. Stem Cells Int (2016) 0.75
Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway. Sci Rep (2016) 0.75
Members of the Cyr61/CTGF/NOV Protein Family: Emerging Players in Hepatic Progenitor Cell Activation and Intrahepatic Cholangiocarcinoma. Gastroenterol Res Pract (2016) 0.75
Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol (2016) 0.75
miR-26a induced the suppression of tumor growth of cholangiocarcinoma via KRT19 approach. Oncotarget (2016) 0.75
Intermediate filament reorganization dynamically influences cancer cell alignment and migration. Sci Rep (2017) 0.75
Keratin 18-deficiency results in steatohepatitis and liver tumors in old mice: A model of steatohepatitis-associated liver carcinogenesis. Oncotarget (2016) 0.75
Hepatocellular carcinoma: How does keratin 19 influence HCC? Nat Rev Gastroenterol Hepatol (2013) 0.75
Mammalian-enabled (MENA) protein enhances oncogenic potential and cancer stem cell-like phenotype in hepatocellular carcinoma cells. FEBS Open Bio (2017) 0.75
Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer. Nat Commun (2017) 0.75
Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res (2010) 18.73
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med (1996) 17.51
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology (2006) 4.61
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med (2012) 3.96
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells (2005) 3.66
ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer (2010) 3.44
Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene (2006) 2.65
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40
Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans. Hepatology (2011) 2.25
The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology (2006) 2.18
Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology (2011) 1.67
Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. Gut (2010) 1.44
Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis (2002) 1.42
Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci (2003) 1.36
Preneoplastic lesions in human hepatocarcinogenesis. Liver Int (2005) 1.33
Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose? J Pathol (2010) 1.31
Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res (2004) 1.28
Alpha v beta3 integrin spatially regulates VASP and RIAM to control adhesion dynamics and migration. J Cell Biol (2010) 1.24
Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology (2011) 1.22
Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int (2008) 1.20
Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res (2008) 1.13
Hepatic progenitor cells: an update. Clin Liver Dis (2010) 1.12
Differential expression of VASP in normal lung tissue and lung adenocarcinomas. Thorax (2005) 1.08
PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets (2009) 1.01
Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer (2008) 1.00
Cytoskeleton-associated proteins: their role as cellular integrators in the neoplastic process. Crit Rev Oncol Hematol (1985) 0.90
Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology (2011) 0.87
Side population (SP) cells: taking center stage in regeneration and liver cancer? Hepatology (2006) 0.85
Melanoma progression in a changing environment. Eur J Cell Biol (2007) 0.80
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology (2008) 5.77
Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med (2009) 5.26
Intrarenal resistive index after renal transplantation. N Engl J Med (2013) 4.19
Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med (2012) 3.96
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology (2012) 3.86
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 3.72
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2006) 3.59
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology (2007) 3.39
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology (2014) 3.23
Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology (2013) 3.06
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol (2013) 2.98
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol (2012) 2.92
Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut (2010) 2.91
The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development (2002) 2.89
From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med (2003) 2.84
Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology (2012) 2.83
Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut (2010) 2.70
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol (2002) 2.65
Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology (2013) 2.64
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2007) 2.47
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40
Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest (2011) 2.36
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Angiogenesis in liver disease. J Hepatol (2008) 2.31
Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol (2003) 2.27
Machine perfusion versus cold storage for preservation of kidneys from expanded criteria donors after brain death. Transpl Int (2011) 2.25
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest (2007) 2.19
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol (2007) 2.14
Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology (2013) 2.12
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem (2006) 2.07
StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut (2011) 2.07
gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut (2009) 2.06
A role for autophagy during hepatic stellate cell activation. J Hepatol (2011) 2.04
Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors. Surg Endosc (2012) 2.04
The β-adrenoceptor agonist isoproterenol rescues acetaminophen-injured livers through increasing progenitor numbers by Wnt in mice. Hepatology (2014) 2.03
Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc (2013) 2.01
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology (2011) 1.94
Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (2013) 1.93
Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol (2006) 1.89
Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol (2009) 1.89
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87
A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res (2005) 1.87
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology (2010) 1.82
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology (2003) 1.79
Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl (2002) 1.79
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74
Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol (2002) 1.74
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology (2003) 1.73